Evaluation of the effects on choroidal thickness of bimatoprost 0.03% versus a brinzolamide 1.0%/ timolol maleate 0.5% fixed combination

被引：14
|
作者：
Akyol, Nurettin [1 ]
Kalkisim, Ahmet [1 ]
Turk, Adem [1 ]
Kola, Mehmet [1 ]
Imamoglu, Halil Ibrahim [1 ]
机构：
[1] Karadeniz Tech Univ, Dept Ophthalmol, Fac Med, Trabzon, Turkey
来源：
CUTANEOUS AND OCULAR TOXICOLOGY | 2017年 / 36卷 / 04期
关键词：
Azarga; bimatoprost; choroid; glaucoma; therapy; tomography; optical coherence; OPTICAL COHERENCE TOMOGRAPHY; OPEN-ANGLE GLAUCOMA; OCULAR PULSE AMPLITUDE; NERVE-FIBER LAYER; INTRAOCULAR-PRESSURE; BLOOD-FLOW; HEALTHY EYES; HYPERTENSION; MANAGEMENT; THERAPY;
D O I：
10.1080/15569527.2017.1315128
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
Objective: To investigate the effects of two different medical treatment options on choroidal thickness (CT) in cases of open-angle glaucoma (OAG). Methods: Sixty-seven eyes newly diagnosed with OAG and 52 healthy eyes constituting the control group were included in the study. Glaucomatous eyes were randomly divided into two subgroups; Group I was started on bimatoprost 0.03% and Group II on a brinzolamide 1.0%/ timolol maleate 0.5% fixed combination (BTFC). Intraocular pressure (IOP), ocular pulse amplitude (OPA) and subfoveal CT measurements were performed in all eyes in the study before treatment and on weeks 2, 4 and 8 after treatment. Results: Mean initial IOP values in groups I and II and the control group were 25.5 +/- 4.7, 25.1 +/- 5.2 and 16.1 +/- 2.9 mmHg, mean OPA values were 3.7 +/- 1, 3.6 +/- 1.4 and 2.4 +/- 0.6mmHg and mean CT values were 269.4 +/- 83, 264.5 +/- 84.4 and 320.1 +/- 56.6 mm, respectively. Eight weeks after treatment, mean IOP values in Groups I and II and the control group were 18.3 +/- 2.6, 18.1 +/- 3.4 and 15.7 +/- 2.9 mmHg, mean OPA values were 2.9 +/- 1.2, 2.8 +/- 1.5 and 2.3 +/- 0.8mmHg and mean CT values were 290.2 +/- 87.3, 271.8 +/- 82.5 and 319.3 +/- 56.8 mm, respectively. No significant difference was determined in terms of the decrease in IOP and OPA obtained after treatment in Group I and Group II. However, a significant difference was observed between the two groups in terms of choroidal thickening after treatment. Conclusion: The use of topical ocular hypotensive medication in eyes with OAG results in an increase in CT. This increase is relatively greater with bimatoprost 0.03% therapy compared to BTFC.
引用
收藏
页码：397 / 403
页数：7
相关论文
共 50 条
  • [1] Safety and efficacy of bimatoprost 0.03% versus timolol maleate 0.5%/dorzolamide 2% fixed combination
    Day, DG
    Sharpe, ED
    Beischel, CJ
    Jenkins, JN
    Stewart, JA
    Stewart, WC
    [J]. EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2005, 15 (03) : 336 - 342
  • [2] Managing refractory glaucoma with a fixed combination of bimatoprost(0.03%) and timolol (0.5%)
    Gheith, Moataz E.
    Mayer, Jason R.
    Siam, Ghada A.
    de Barros, Daniela S. Monteiro
    Thomas, Tricia L.
    Katz, L. Jay
    [J]. CLINICAL OPHTHALMOLOGY, 2008, 2 (01): : 15 - 19
  • [3] Intraocular Pressure Reduction With Bimatoprost 0.03% and the Bimatoprost 0.03%/Timolol 0.5% Fixed Combination in Glaucoma and Ocular Hypertension
    Katsanos, A.
    Dastiridou, A. I.
    Fanariotis, M.
    Kotoula, M. G.
    Cholevas, P.
    Tsironi, E.
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [4] Travoprost 0.004%/timolol 0.5% fixed combination in patients transitioning from fixed or unfixed bimatoprost 0.03%/timolol 0.5%
    Maria-Luise Scherzer
    Ivana Liehneova
    Francisco Jose Muñoz Negrete
    Dietmar Schnober
    [J]. Advances in Therapy, 2011, 28 : 661 - 670
  • [5] Travoprost 0.004%/timolol 0.5% fixed combination in patients transitioning from fixed or unfixed bimatoprost 0.03%/timolol 0.5%
    Scherzer, Maria-Luise
    Liehneova, Ivana
    Munoz Negrete, Francisco Jose
    Schnober, Dietmar
    [J]. ADVANCES IN THERAPY, 2011, 28 (08) : 661 - 670
  • [6] TWENTY-FOUR HOUR DIURNAL CURVE COMPARISON OF COMMERCIALLY AVAILABLE BIMATOPROST 0.03% VERSUS TIMOLOL MALEATE 0.5%/OORZOLAMIDE 2% FIXED COMBINATION
    D.G.Day
    E.D.Sharpe
    C.J.Beischel
    J.N.Leech
    J.A.Stewart
    W.C.Stewart
    [J]. 国际眼科杂志, 2003, (01) : 98 - 98
  • [7] Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops
    Inoue, Kenji
    Shiokawa, Minako
    Ishida, Kyoko
    Tomita, Goji
    [J]. CLINICAL OPHTHALMOLOGY, 2015, 9 : 619 - 623
  • [8] Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy
    Schnober, Dietmar
    Hubatsch, Douglas A.
    Scherzer, Maria-Luise
    [J]. CLINICAL OPHTHALMOLOGY, 2015, 9 : 825 - 832
  • [9] Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
    Pfennigsdorf, Stefan
    Eschstruth, Peter
    Haesemeyer, Stefan
    Feuerhake, Cord
    Brief, Gerrett
    Grobeiu, Ioana
    Shirlaw, Andrew
    [J]. CLINICAL OPHTHALMOLOGY, 2016, 10 : 1837 - 1846
  • [10] Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%
    Kaback, Martin
    Scoper, Stephen V.
    Arzeno, George
    James, John E.
    Hua, Steven Y.
    Salem, Craig
    Dickerson, Jaime E.
    Landry, Theresa A.
    Bergamini, Michael V. W.
    [J]. OPHTHALMOLOGY, 2008, 115 (10) : 1728 - 1734
12345